NDAORALTABLET, CHEWABLE, TABLET
Approved
Jul 2013
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
3/8 — Basic
LO MINASTRIN FE (ethinyl estradiol; norethindrone acetate) by Dr. Reddy's Laboratories. Approved for pregnancy. First approved in 2013.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lo Minastrin FE is an oral contraceptive tablet containing ethinyl estradiol and norethindrone acetate, approved in 2013 for pregnancy prevention. It is a combined hormonal contraceptive that works by suppressing ovulation and altering cervical mucus to prevent fertilization. The formulation includes chewable and standard tablet options for flexible dosing.
LOE Approaching2.7 years to LOE
Product is in late-stage maturity with 2.8 years until loss of exclusivity, signaling declining team investment and transition planning opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Why This Matters for Your Career
Worked on LO MINASTRIN FE at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.